TapewireFind a company

person · Reporting owner

RAKIN KEVIN

Disclosed activity across 4 companies

Tapewire entity
38103
SEC CIK
0001184421

Export transaction history ↓

Reported relationships

Latest disclosed role at each company.

CompanyLast reported asReport datePublished
ELUTIA INC.ELUT · Entity 7342Director · 10% ownerJune 11, 2026June 15, 2026
ORAMED PHARMACEUTICALS INC.ORMP · Entity 6311DirectorMarch 21, 2022March 23, 2022
Ocugen, Inc.HSGX · Entity 5550DirectorFebruary 08, 2019February 11, 2019
Quantum-Si IncQSI · Entity 6440DirectorMay 18, 2026May 20, 2026

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

ELUTIA INC.

Report date June 11, 2026 · Filed June 15, 2026

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.96 · Expires 2036-06-11Direct159,590 Reported balance After 2026-06-11 transaction · row 1 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 1 · 2026-06-11 · Grant · Acquired 159,590 · Balance 159,590

F1: This option was granted automatically under the Issuer's Non-Employee Director Compensation Program and vests and becomes exercisable on the earlier of (i) the day immediately preceding the date of the Issuer's first annual meeting following the date of grant and (ii) the first anniversary of the date of grant, subject to the Reporting Person's continuing in service on the Issuer's board of directors through the applicable vesting date.

Filing footnotes · ownership attribution and instrument terms

F1: This option was granted automatically under the Issuer's Non-Employee Director Compensation Program and vests and becomes exercisable on the earlier of (i) the day immediately preceding the date of the Issuer's first annual meeting following the date of grant and (ii) the first anniversary of the date of grant, subject to the Reporting Person's continuing in service on the Issuer's board of directors through the applicable vesting date.

ORAMED PHARMACEUTICALS INC.

Report date March 21, 2022 · Filed March 23, 2022

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common StockSEC Table I · non-derivativeDirect46,661 Reported balance After 2022-03-21 transaction · row 1
1 source row

Row 1 · 2022-03-21 · Sale · Disposed 10,000 · Balance 46,661

Ocugen, Inc.

Report date February 08, 2019 · Filed February 11, 2019

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common StockSEC Table I · non-derivativeDirect418,639 Reported balance After 2019-02-08 transaction · row 1
1 source row

Row 1 · 2019-02-08 · Exercise / conversion · Acquired 173,076 · Balance 418,639

F1: The per share exercise price of each Common Stock Warrant was re-priced to $0.01 pursuant to a warrant exercise agreement entered into with the Issuer on February 8, 2019.

Common StockSEC Table I · non-derivativeIndirectSee Footnote66,666 Reported balance After 2019-02-08 transaction · row 2 Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source row

Row 2 · 2019-02-08 · Exercise / conversion · Acquired 33,333 · Balance 66,666

F1: The per share exercise price of each Common Stock Warrant was re-priced to $0.01 pursuant to a warrant exercise agreement entered into with the Issuer on February 8, 2019.

F2: The reportable securities are owned by the Alison N Hoffman and Kevin L Rakin Irrevocable Trust For Sarah Hoffman Rakin. The Reporting Person disclaims beneficial ownership of these shares and this report shall not be deemed an admission that he is the beneficial owner of such shares for purposes of Section 16 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or for any other purpose, except to the extent of his pecuniary interest therein.

Common StockSEC Table I · non-derivativeIndirectSee Footnote66,666 Reported balance After 2019-02-08 transaction · row 3 Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source row

Row 3 · 2019-02-08 · Exercise / conversion · Acquired 33,333 · Balance 66,666

F1: The per share exercise price of each Common Stock Warrant was re-priced to $0.01 pursuant to a warrant exercise agreement entered into with the Issuer on February 8, 2019.

F3: The reportable securities are owned by the Alison N Hoffman and Kevin L Rakin Irrevocable Trust For Julia Hoffman Rakin. The Reporting Person disclaims beneficial ownership of these shares and this report shall not be deemed an admission that he is the beneficial owner of such shares for purposes of Section 16 of the Exchange Act or for any other purpose, except to the extent of his pecuniary interest therein.

Common StockSEC Table I · non-derivativeIndirectSee Footnote257,846 Reported balance After 2019-02-08 transaction · row 4 Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source row

Row 4 · 2019-02-08 · Exercise / conversion · Acquired 111,111 · Balance 257,846

F1: The per share exercise price of each Common Stock Warrant was re-priced to $0.01 pursuant to a warrant exercise agreement entered into with the Issuer on February 8, 2019.

F4: The reportable securities are owned by the Kevin L Rakin Irrevocable Trust. The Reporting Person disclaims beneficial ownership of these shares and this report shall not be deemed an admission that he is the beneficial owner of such shares for purposes of Section 16 of the Exchange Act or for any other purpose, except to the extent of his pecuniary interest therein.

Common Stock Warrant (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.01 · Expires 2023-10-10Direct0 Reported balance After 2019-02-08 transaction · row 5 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 5 · 2019-02-08 · Exercise / conversion · Disposed 173,076 · Balance 0

F1: The per share exercise price of each Common Stock Warrant was re-priced to $0.01 pursuant to a warrant exercise agreement entered into with the Issuer on February 8, 2019.

Common Stock Warrant (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.01 · Expires 2021-11-22IndirectSee Footnote0 Reported balance After 2019-02-08 transaction · row 6 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 6 · 2019-02-08 · Exercise / conversion · Disposed 33,333 · Balance 0

F1: The per share exercise price of each Common Stock Warrant was re-priced to $0.01 pursuant to a warrant exercise agreement entered into with the Issuer on February 8, 2019.

F2: The reportable securities are owned by the Alison N Hoffman and Kevin L Rakin Irrevocable Trust For Sarah Hoffman Rakin. The Reporting Person disclaims beneficial ownership of these shares and this report shall not be deemed an admission that he is the beneficial owner of such shares for purposes of Section 16 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or for any other purpose, except to the extent of his pecuniary interest therein.

Common Stock Warrant (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.01 · Expires 2021-11-22IndirectSee Footnote0 Reported balance After 2019-02-08 transaction · row 7 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 7 · 2019-02-08 · Exercise / conversion · Disposed 33,333 · Balance 0

F1: The per share exercise price of each Common Stock Warrant was re-priced to $0.01 pursuant to a warrant exercise agreement entered into with the Issuer on February 8, 2019.

F3: The reportable securities are owned by the Alison N Hoffman and Kevin L Rakin Irrevocable Trust For Julia Hoffman Rakin. The Reporting Person disclaims beneficial ownership of these shares and this report shall not be deemed an admission that he is the beneficial owner of such shares for purposes of Section 16 of the Exchange Act or for any other purpose, except to the extent of his pecuniary interest therein.

Common Stock Warrant (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.01 · Expires 2021-11-22IndirectSee Footnote0 Reported balance After 2019-02-08 transaction · row 8 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 8 · 2019-02-08 · Exercise / conversion · Disposed 111,111 · Balance 0

F1: The per share exercise price of each Common Stock Warrant was re-priced to $0.01 pursuant to a warrant exercise agreement entered into with the Issuer on February 8, 2019.

F4: The reportable securities are owned by the Kevin L Rakin Irrevocable Trust. The Reporting Person disclaims beneficial ownership of these shares and this report shall not be deemed an admission that he is the beneficial owner of such shares for purposes of Section 16 of the Exchange Act or for any other purpose, except to the extent of his pecuniary interest therein.

Filing footnotes · ownership attribution and instrument terms

F1: The per share exercise price of each Common Stock Warrant was re-priced to $0.01 pursuant to a warrant exercise agreement entered into with the Issuer on February 8, 2019.

F2: The reportable securities are owned by the Alison N Hoffman and Kevin L Rakin Irrevocable Trust For Sarah Hoffman Rakin. The Reporting Person disclaims beneficial ownership of these shares and this report shall not be deemed an admission that he is the beneficial owner of such shares for purposes of Section 16 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or for any other purpose, except to the extent of his pecuniary interest therein.

F3: The reportable securities are owned by the Alison N Hoffman and Kevin L Rakin Irrevocable Trust For Julia Hoffman Rakin. The Reporting Person disclaims beneficial ownership of these shares and this report shall not be deemed an admission that he is the beneficial owner of such shares for purposes of Section 16 of the Exchange Act or for any other purpose, except to the extent of his pecuniary interest therein.

F4: The reportable securities are owned by the Kevin L Rakin Irrevocable Trust. The Reporting Person disclaims beneficial ownership of these shares and this report shall not be deemed an admission that he is the beneficial owner of such shares for purposes of Section 16 of the Exchange Act or for any other purpose, except to the extent of his pecuniary interest therein.

Quantum-Si Inc

Report date May 18, 2026 · Filed May 20, 2026

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.85 · Expires 2036-05-18Direct251,185 Reported balance After 2026-05-18 transaction · row 3 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 3 · 2026-05-18 · Grant · Acquired 251,185 · Balance 251,185

F3: The shares underlying this option vest on the date of the Issuer's next regular annual stockholders meeting, subject to continued service through the applicable vesting date.

Class A Common StockSEC Table I · non-derivativeIndirectSee Footnote1,200,000 Reported balance Holding disclosure · report date 2026-05-18 · row 1 Holding and transaction disclosures are not merged.
1 source row

Row 1 · Balance 1,200,000

F1: HighCape Partners QSI II Invest, L.P. distributed in kind these shares of the Company's Class A common stock to its limited partners on a pro rata basis, for no consideration.

F2: Consists of (i) 24,527 shares of the Company's Class A common stock held by HighCape Partners II, L.P. and (ii) 1,175,473 shares of the Company's Class A common stock held by HighCape Partners QP II, L.P. Mr. Rakin is the managing member of HighCape Capital II GP, LLC, which is the general partner of HighCape Partners II GP, L.P., which is the general partner of each of HighCape Partners II, L.P. and HighCape Partners QP II, L.P., and as a result each may be deemed to share voting and investment discretion with respect to the Class A common stock held by such entities.

Class A Common StockSEC Table I · non-derivativeDirect20,512 Reported balance Holding disclosure · report date 2026-05-18 · row 2 Holding and transaction disclosures are not merged.
1 source row

Row 2 · Balance 20,512

Filing footnotes · ownership attribution and instrument terms

F1: HighCape Partners QSI II Invest, L.P. distributed in kind these shares of the Company's Class A common stock to its limited partners on a pro rata basis, for no consideration.

F2: Consists of (i) 24,527 shares of the Company's Class A common stock held by HighCape Partners II, L.P. and (ii) 1,175,473 shares of the Company's Class A common stock held by HighCape Partners QP II, L.P. Mr. Rakin is the managing member of HighCape Capital II GP, LLC, which is the general partner of HighCape Partners II GP, L.P., which is the general partner of each of HighCape Partners II, L.P. and HighCape Partners QP II, L.P., and as a result each may be deemed to share voting and investment discretion with respect to the Class A common stock held by such entities.

F3: The shares underlying this option vest on the date of the Issuer's next regular annual stockholders meeting, subject to continued service through the applicable vesting date.

Transaction history

JSON API
Reset

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction dateCompanyActivity / securityShares / unitsReported priceReported valueDetails
August 09, 2021 Filed Aug 11, 2021 21:15 UTC ORAMED PHARMACEUTICALS INC. ORMP · Entity 6311 Tax withholdingCommon Stock 1,977 $21.09 $41,694.93
Disclosure

SEC source: 0001213900-21-041712 · ownership.xml · nonDerivative · entry 6

RAKIN KEVIN · CIK 0001184421 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 32,247

F3 · shares: Represents a cashless exercise of outstanding stock options to purchase 10,000 shares of common stock. The reporting person received 8,023 shares of common stock and surrendered 1,977 shares of common stock underlying the stock option in payment of the exercise price.

Read SEC document
August 09, 2021 Filed Aug 11, 2021 21:15 UTC ORAMED PHARMACEUTICALS INC. ORMP · Entity 6311 Exercise / conversionCommon Stock 10,000 $4.17 $41,700.00
Disclosure

SEC source: 0001213900-21-041712 · ownership.xml · nonDerivative · entry 5

RAKIN KEVIN · CIK 0001184421 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 34,224

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
August 09, 2021 Filed Aug 11, 2021 21:15 UTC ORAMED PHARMACEUTICALS INC. ORMP · Entity 6311 Tax withholdingCommon Stock 1,517 $21.09 $31,993.53
Disclosure

SEC source: 0001213900-21-041712 · ownership.xml · nonDerivative · entry 4

RAKIN KEVIN · CIK 0001184421 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 24,224

F2 · shares: Represents a cashless exercise of outstanding stock options to purchase 6,666 shares of common stock. The reporting person received 5,149 shares of common stock and surrendered 1,517 shares of common stock underlying the stock option in payment of the exercise price.

Read SEC document
August 09, 2021 Filed Aug 11, 2021 21:15 UTC ORAMED PHARMACEUTICALS INC. ORMP · Entity 6311 Exercise / conversionCommon Stock 6,666 $4.80 $31,996.80
Disclosure

SEC source: 0001213900-21-041712 · ownership.xml · nonDerivative · entry 3

RAKIN KEVIN · CIK 0001184421 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 25,741

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
August 09, 2021 Filed Aug 11, 2021 21:15 UTC ORAMED PHARMACEUTICALS INC. ORMP · Entity 6311 Tax withholdingCommon Stock 1,683 $21.09 $35,494.47
Disclosure

SEC source: 0001213900-21-041712 · ownership.xml · nonDerivative · entry 2

RAKIN KEVIN · CIK 0001184421 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 19,075

F1 · shares: Represents a cashless exercise of outstanding stock options to purchase 5,697 shares of common stock. The reporting person received 4,014 shares of common stock and surrendered 1,683 shares of common stock underlying the stock option in payment of the exercise price.

Read SEC document
August 09, 2021 Filed Aug 11, 2021 21:15 UTC ORAMED PHARMACEUTICALS INC. ORMP · Entity 6311 Exercise / conversionCommon Stock 5,697 $6.23 $35,492.31
Disclosure

SEC source: 0001213900-21-041712 · ownership.xml · nonDerivative · entry 1

RAKIN KEVIN · CIK 0001184421 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 20,758

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
June 11, 2021 Filed Jun 15, 2021 21:27 UTC Quantum-Si Inc QSI · Entity 6440 GrantClass A Common Stock 20,512 $0.00 $0.00
Disclosure

SEC source: 0001104659-21-081583 · tm2119549-25_4seq1.xml · nonDerivative · entry 2

RAKIN KEVIN · CIK 0001184421 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 20,512

F4 · shares: Consists of restricted stock units ("RSUs"). Each RSU represents the right to receive one share of common stock upon vesting. The RSUs vest in equal annual installments over three years beginning on June 11, 2022, subject to Mr. Rakin's continued service through the applicable vesting date.

Read SEC document
June 10, 2021 Filed Jun 15, 2021 21:27 UTC Quantum-Si Inc QSI · Entity 6440 GrantClass A Common Stock 1,901,000 $10.00 $19,010,000.00
Disclosure

SEC source: 0001104659-21-081583 · tm2119549-25_4seq1.xml · nonDerivative · entry 1

RAKIN KEVIN · CIK 0001184421 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 1,901,000

F1 · shares: Consists of (i) 100,000 shares of the Company's Class A common stock held by Mr. Rakin and the Kevin L. Rakin Irrevocable Trust, (ii) 601,000 shares of the Company's Class A common stock held by HighCape Partners QSI II Invest, L.P, (iii) 24,527 shares of the Company's Class A common stock held by HighCape Partners II, L.P. and

F2 · shares: (iv) 1,175,473 shares of the Company's Class A common stock held by HighCape Partners QP II, L.P. Mr. Rakin and Matt Zuga are the managing members of HighCape Capital II GP, LLC, which is the general partner of HighCape Partners II GP, L.P., which is the general partner of each of HighCape Partners QSI II Invest, L.P, HighCape Partners II, L.P. and HighCape Partners QP II, L.P., and as a result each may be deemed to share voting and investment discretion with respect to the common stock held by such entities. Mr. Rakin disclaims any beneficial ownership of the securities to be held by HighCape Partners QSI II Invest, L.P, HighCape Partners II, L.P. and HighCape Partners QP II, L.P. other than to the extent of any pecuniary interest he may have therein, directly or indirectly.

F3 · shares: In connection with the closing of the transactions (the "Business Combination") contemplated by the Business Combination Agreement, dated as of February 18, 2021, by and among HighCape Capital Acquisition Corp. ("HighCape"), Tenet Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of HighCape ("Merger Sub"), and Quantum-Si Incorporated, a Delaware corporation ("Quantum-Si"), pursuant to which Merger Sub merged with and into Quantum-Si (the "Merger"), with Quantum-Si surviving as a wholly-owned subsidiary of HighCape (which changed its name to "Quantum-Si Incorporated", the "Issuer"), these shares were purchased, at a price of $10.00 per share, in a private placement immediately prior to the closing of the Merger.

F1 · ownership.nature: Consists of (i) 100,000 shares of the Company's Class A common stock held by Mr. Rakin and the Kevin L. Rakin Irrevocable Trust, (ii) 601,000 shares of the Company's Class A common stock held by HighCape Partners QSI II Invest, L.P, (iii) 24,527 shares of the Company's Class A common stock held by HighCape Partners II, L.P. and

Read SEC document
June 07, 2021 Filed Jun 9, 2021 21:44 UTC ELUTIA INC. AZYO · Entity 7342 GrantStock Option (Right to Buy) · Derivative 14,082 $0.00 Strike: $10.41 $0.00
Disclosure

SEC source: 0001415889-21-002895 · form4-06092021_020617.xml · derivative · entry 2

HighCape Capital, L.P. · CIK 0001826279 · Director · 10% owner

HIGHCAPE PARTNERS, L.P. · CIK 0001598046 · 10% owner

HIGHCAPE PARTNERS QP, L.P. · CIK 0001598026 · 10% owner

HighCape Partners GP, LLC · CIK 0001819933 · 10% owner

HighCape Partners GP, L.P. · CIK 0001819932 · 10% owner

HighCape Co-Investment Vehicle I, LLC · CIK 0001819988 · 10% owner

HighCape Co-Investment Vehicle II, LLC · CIK 0001820044 · Director · 10% owner

HighCape Capital, LLC · CIK 0001827500 · 10% owner

Zuga Matt · CIK 0001790214 · Director · 10% owner

RAKIN KEVIN · CIK 0001184421 · Director · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 14,082

Underlying: Class A Common Stock · 14,082 shares

Expires 2031-06-06

F1 · derivative.exercise_date: This option was granted automatically under the Issuer's Non-Employee Director Compensation Program and vests and becomes exercisable on the earlier of (i) the day immediately preceding the date of the Issuer's first annual meeting following the date of grant and (ii) the first anniversary of the date of grant, subject to Messrs. Rakin's and Zuga's, as applicable, continuing in service on the Issuer's board of directors through the applicable vesting date.

F3 · ownership.nature: Held by W. Matthew Zuga as non-employee member of the Issuer's board of directors

Read SEC document
June 07, 2021 Filed Jun 9, 2021 21:44 UTC ELUTIA INC. AZYO · Entity 7342 GrantStock Option (Right to Buy) · Derivative 14,082 $0.00 Strike: $10.41 $0.00
Disclosure

SEC source: 0001415889-21-002895 · form4-06092021_020617.xml · derivative · entry 1

HighCape Capital, L.P. · CIK 0001826279 · Director · 10% owner

HIGHCAPE PARTNERS, L.P. · CIK 0001598046 · 10% owner

HIGHCAPE PARTNERS QP, L.P. · CIK 0001598026 · 10% owner

HighCape Partners GP, LLC · CIK 0001819933 · 10% owner

HighCape Partners GP, L.P. · CIK 0001819932 · 10% owner

HighCape Co-Investment Vehicle I, LLC · CIK 0001819988 · 10% owner

HighCape Co-Investment Vehicle II, LLC · CIK 0001820044 · Director · 10% owner

HighCape Capital, LLC · CIK 0001827500 · 10% owner

Zuga Matt · CIK 0001790214 · Director · 10% owner

RAKIN KEVIN · CIK 0001184421 · Director · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 14,082

Underlying: Class A Common Stock · 14,082 shares

Expires 2031-06-06

F1 · derivative.exercise_date: This option was granted automatically under the Issuer's Non-Employee Director Compensation Program and vests and becomes exercisable on the earlier of (i) the day immediately preceding the date of the Issuer's first annual meeting following the date of grant and (ii) the first anniversary of the date of grant, subject to Messrs. Rakin's and Zuga's, as applicable, continuing in service on the Issuer's board of directors through the applicable vesting date.

F2 · ownership.nature: Held by Kevin L. Rakin as non-employee member of the Issuer's board of directors

Read SEC document
February 17, 2021 Filed Feb 17, 2021 21:21 UTC ORAMED PHARMACEUTICALS INC. ORMP · Entity 6311 GrantStock Option (right to buy) · Derivative 15,000 $0.00 Strike: $11.33 $0.00
Disclosure

SEC source: 0001213900-21-010094 · ownership.xml · derivative · entry 1

RAKIN KEVIN · CIK 0001184421 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 15,000

Underlying: Common Stock · 15,000 shares

Expires 2031-02-17

F1 · kind: The Stock Option will vest in 4 equal installments as follows: 3,750 shall vest on each of December 31, 2021, December 31, 2022, December 31, 2023 and December 31, 2024.

F1 · derivative.exercise_date: The Stock Option will vest in 4 equal installments as follows: 3,750 shall vest on each of December 31, 2021, December 31, 2022, December 31, 2023 and December 31, 2024.

Read SEC document
October 13, 2020 Filed Oct 14, 2020 01:57 UTC ELUTIA INC. AZYO · Entity 7342 OtherWarrant · Derivative 7,655 $0.00 Strike: $5.44 $0.00
Disclosure

SEC source: 0001104659-20-114637 · a4.xml · derivative · entry 7

HighCape Capital, L.P. · CIK 0001826279 · 10% owner

HIGHCAPE PARTNERS, L.P. · CIK 0001598046 · 10% owner

HIGHCAPE PARTNERS QP, L.P. · CIK 0001598026 · 10% owner

HighCape Partners GP, LLC · CIK 0001819933 · 10% owner

HighCape Partners GP, L.P. · CIK 0001819932 · 10% owner

HighCape Co-Investment Vehicle I, LLC · CIK 0001819988 · 10% owner

HighCape Co-Investment Vehicle II, LLC · CIK 0001820044 · 10% owner

HighCape Capital, LLC · CIK 0001827500 · 10% owner

Zuga Matt · CIK 0001790214 · Director · 10% owner

RAKIN KEVIN · CIK 0001184421 · Director · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · Footnote

Disclosed balance after: 0

Underlying: Class A Common Stock · 7,655 shares

Expires 2027-03-01

F2 · ownership.nature: Kevin Rakin and W. Matthew Zuga, members of Issuer's board of directors, are the managing members of HighCape Partners GP, LLC, which in turn is the general partner of HighCape Partners GP, L.P., which in turn is the general partner of each of HighCape Partners, L.P. and HighCape Partners QP, L.P. Mr. Rakin and Mr. Zuga are the managing members of HighCape Capital, LLC, which in turn is the general partner of HighCape Capital, L.P. Each of Mr. Rakin, Mr. Zuga, HighCape Partners GP, LLC and HighCape Partners GP, L.P. may be deemed to beneficially own the securities held by HighCape Partners, L.P. and HighCape Partners QP, L.P., and each of Mr. Rakin, Mr. Zuga and HighCape Capital, LLC may be deemed to beneficially own the securities held by HighCape Capital, L.P.

F4 · ownership.nature: HighCape Partners QP, L.P. is the record holder of these securities.

Read SEC document
October 13, 2020 Filed Oct 14, 2020 01:57 UTC ELUTIA INC. AZYO · Entity 7342 ConversionSeries A Convertible Preferred Stock · Derivative 31,133,977 $0.00 $0.00
Disclosure

SEC source: 0001104659-20-114637 · a4.xml · derivative · entry 6

HighCape Capital, L.P. · CIK 0001826279 · 10% owner

HIGHCAPE PARTNERS, L.P. · CIK 0001598046 · 10% owner

HIGHCAPE PARTNERS QP, L.P. · CIK 0001598026 · 10% owner

HighCape Partners GP, LLC · CIK 0001819933 · 10% owner

HighCape Partners GP, L.P. · CIK 0001819932 · 10% owner

HighCape Co-Investment Vehicle I, LLC · CIK 0001819988 · 10% owner

HighCape Co-Investment Vehicle II, LLC · CIK 0001820044 · 10% owner

HighCape Capital, LLC · CIK 0001827500 · 10% owner

Zuga Matt · CIK 0001790214 · Director · 10% owner

RAKIN KEVIN · CIK 0001184421 · Director · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · Footnote

Disclosed balance after: 0

Underlying: Class A Common Stock · 4,062,451 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F6 · derivative.exercise_price: Each share of Series A preferred stock was automatically converted into 0.071659417 shares of Class A common stock upon the closing of the Issuer's initial public offering. In addition, immediately prior to the consummation of the Issuer's underwritten initial public offering of its Class A common stock, each holder of Series A preferred stockholders received, for each share of Series A preferred stock then held, 0.820876470 shares of Class A common stock (the quotient of $13.9549 divided by $17.00, the price per share of Class A common stock in such offering).

F6 · derivative.exercise_date: Each share of Series A preferred stock was automatically converted into 0.071659417 shares of Class A common stock upon the closing of the Issuer's initial public offering. In addition, immediately prior to the consummation of the Issuer's underwritten initial public offering of its Class A common stock, each holder of Series A preferred stockholders received, for each share of Series A preferred stock then held, 0.820876470 shares of Class A common stock (the quotient of $13.9549 divided by $17.00, the price per share of Class A common stock in such offering).

F6 · derivative.expiration_date: Each share of Series A preferred stock was automatically converted into 0.071659417 shares of Class A common stock upon the closing of the Issuer's initial public offering. In addition, immediately prior to the consummation of the Issuer's underwritten initial public offering of its Class A common stock, each holder of Series A preferred stockholders received, for each share of Series A preferred stock then held, 0.820876470 shares of Class A common stock (the quotient of $13.9549 divided by $17.00, the price per share of Class A common stock in such offering).

F1 · ownership.nature: Consists of (i) 43,255 shares of Class A common stock held by HighCape Partners, L.P.; (ii) 3,211,838 shares of Class A common stock held by HighCape Partners QP, L.P.; (iii) 499,145 shares of Class A common stock held by HighCape Co-Investment Vehicle I, LLC; (iv) 259,282 shares of Class A common stock held by HighCape Co-Investment Vehicle II, LLC and (v) 48,931 shares of Class A common stock held by HighCape Capital, L.P.

F2 · ownership.nature: Kevin Rakin and W. Matthew Zuga, members of Issuer's board of directors, are the managing members of HighCape Partners GP, LLC, which in turn is the general partner of HighCape Partners GP, L.P., which in turn is the general partner of each of HighCape Partners, L.P. and HighCape Partners QP, L.P. Mr. Rakin and Mr. Zuga are the managing members of HighCape Capital, LLC, which in turn is the general partner of HighCape Capital, L.P. Each of Mr. Rakin, Mr. Zuga, HighCape Partners GP, LLC and HighCape Partners GP, L.P. may be deemed to beneficially own the securities held by HighCape Partners, L.P. and HighCape Partners QP, L.P., and each of Mr. Rakin, Mr. Zuga and HighCape Capital, LLC may be deemed to beneficially own the securities held by HighCape Capital, L.P.

F3 · ownership.nature: In addition, Mr. Zuga is the managing member of each of HighCape Co-Investment Vehicle I, LLC and HighCape Co-Investment Vehicle II, LLC and may be deemed to beneficially own the securities held by such entities. Each of the reporting persons disclaims beneficial ownership of the securities held by the other reporting persons except to the extent of each reporting person's pecuniary interest therein, if any.

Read SEC document
October 13, 2020 Filed Oct 14, 2020 01:57 UTC ELUTIA INC. AZYO · Entity 7342 PurchaseClass A Common Stock 441,176 $17.00 $7,499,992.00
Disclosure

SEC source: 0001104659-20-114637 · a4.xml · nonDerivative · entry 4

HighCape Capital, L.P. · CIK 0001826279 · 10% owner

HIGHCAPE PARTNERS, L.P. · CIK 0001598046 · 10% owner

HIGHCAPE PARTNERS QP, L.P. · CIK 0001598026 · 10% owner

HighCape Partners GP, LLC · CIK 0001819933 · 10% owner

HighCape Partners GP, L.P. · CIK 0001819932 · 10% owner

HighCape Co-Investment Vehicle I, LLC · CIK 0001819988 · 10% owner

HighCape Co-Investment Vehicle II, LLC · CIK 0001820044 · 10% owner

HighCape Capital, LLC · CIK 0001827500 · 10% owner

Zuga Matt · CIK 0001790214 · Director · 10% owner

RAKIN KEVIN · CIK 0001184421 · Director · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · Footnote

Disclosed balance after: 4,508,831

F2 · ownership.nature: Kevin Rakin and W. Matthew Zuga, members of Issuer's board of directors, are the managing members of HighCape Partners GP, LLC, which in turn is the general partner of HighCape Partners GP, L.P., which in turn is the general partner of each of HighCape Partners, L.P. and HighCape Partners QP, L.P. Mr. Rakin and Mr. Zuga are the managing members of HighCape Capital, LLC, which in turn is the general partner of HighCape Capital, L.P. Each of Mr. Rakin, Mr. Zuga, HighCape Partners GP, LLC and HighCape Partners GP, L.P. may be deemed to beneficially own the securities held by HighCape Partners, L.P. and HighCape Partners QP, L.P., and each of Mr. Rakin, Mr. Zuga and HighCape Capital, LLC may be deemed to beneficially own the securities held by HighCape Capital, L.P.

F3 · ownership.nature: In addition, Mr. Zuga is the managing member of each of HighCape Co-Investment Vehicle I, LLC and HighCape Co-Investment Vehicle II, LLC and may be deemed to beneficially own the securities held by such entities. Each of the reporting persons disclaims beneficial ownership of the securities held by the other reporting persons except to the extent of each reporting person's pecuniary interest therein, if any.

F5 · ownership.nature: Consists of (i) 49,118 shares of Class A common stock held by HighCape Partners, L.P.; (ii) 3,652,355 shares of Class A common stock held by HighCape Partners QP, L.P.; (iii) 499,145 shares of Class A common stock held by HighCape Co-Investment Vehicle I, LLC; (iv) 259,282 shares of Class A common stock held by HighCape Co-Investment Vehicle II, LLC and (v) 48,931 shares of Class A common stock held by HighCape Capital, L.P.

Read SEC document
October 13, 2020 Filed Oct 14, 2020 01:57 UTC ELUTIA INC. AZYO · Entity 7342 Tax withholdingClass A Common Stock 2,451 $5.44 $13,339.32
Disclosure

SEC source: 0001104659-20-114637 · a4.xml · nonDerivative · entry 3

HighCape Capital, L.P. · CIK 0001826279 · 10% owner

HIGHCAPE PARTNERS, L.P. · CIK 0001598046 · 10% owner

HIGHCAPE PARTNERS QP, L.P. · CIK 0001598026 · 10% owner

HighCape Partners GP, LLC · CIK 0001819933 · 10% owner

HighCape Partners GP, L.P. · CIK 0001819932 · 10% owner

HighCape Co-Investment Vehicle I, LLC · CIK 0001819988 · 10% owner

HighCape Co-Investment Vehicle II, LLC · CIK 0001820044 · 10% owner

HighCape Capital, LLC · CIK 0001827500 · 10% owner

Zuga Matt · CIK 0001790214 · Director · 10% owner

RAKIN KEVIN · CIK 0001184421 · Director · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · Footnote

Disclosed balance after: 4,067,655

F2 · ownership.nature: Kevin Rakin and W. Matthew Zuga, members of Issuer's board of directors, are the managing members of HighCape Partners GP, LLC, which in turn is the general partner of HighCape Partners GP, L.P., which in turn is the general partner of each of HighCape Partners, L.P. and HighCape Partners QP, L.P. Mr. Rakin and Mr. Zuga are the managing members of HighCape Capital, LLC, which in turn is the general partner of HighCape Capital, L.P. Each of Mr. Rakin, Mr. Zuga, HighCape Partners GP, LLC and HighCape Partners GP, L.P. may be deemed to beneficially own the securities held by HighCape Partners, L.P. and HighCape Partners QP, L.P., and each of Mr. Rakin, Mr. Zuga and HighCape Capital, LLC may be deemed to beneficially own the securities held by HighCape Capital, L.P.

F3 · ownership.nature: In addition, Mr. Zuga is the managing member of each of HighCape Co-Investment Vehicle I, LLC and HighCape Co-Investment Vehicle II, LLC and may be deemed to beneficially own the securities held by such entities. Each of the reporting persons disclaims beneficial ownership of the securities held by the other reporting persons except to the extent of each reporting person's pecuniary interest therein, if any.

F4 · ownership.nature: HighCape Partners QP, L.P. is the record holder of these securities.

Read SEC document
October 13, 2020 Filed Oct 14, 2020 01:57 UTC ELUTIA INC. AZYO · Entity 7342 OtherClass A Common Stock 7,655 $5.44 $41,661.57
Disclosure

SEC source: 0001104659-20-114637 · a4.xml · nonDerivative · entry 2

HighCape Capital, L.P. · CIK 0001826279 · 10% owner

HIGHCAPE PARTNERS, L.P. · CIK 0001598046 · 10% owner

HIGHCAPE PARTNERS QP, L.P. · CIK 0001598026 · 10% owner

HighCape Partners GP, LLC · CIK 0001819933 · 10% owner

HighCape Partners GP, L.P. · CIK 0001819932 · 10% owner

HighCape Co-Investment Vehicle I, LLC · CIK 0001819988 · 10% owner

HighCape Co-Investment Vehicle II, LLC · CIK 0001820044 · 10% owner

HighCape Capital, LLC · CIK 0001827500 · 10% owner

Zuga Matt · CIK 0001790214 · Director · 10% owner

RAKIN KEVIN · CIK 0001184421 · Director · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · Footnote

Disclosed balance after: 4,070,106

F2 · ownership.nature: Kevin Rakin and W. Matthew Zuga, members of Issuer's board of directors, are the managing members of HighCape Partners GP, LLC, which in turn is the general partner of HighCape Partners GP, L.P., which in turn is the general partner of each of HighCape Partners, L.P. and HighCape Partners QP, L.P. Mr. Rakin and Mr. Zuga are the managing members of HighCape Capital, LLC, which in turn is the general partner of HighCape Capital, L.P. Each of Mr. Rakin, Mr. Zuga, HighCape Partners GP, LLC and HighCape Partners GP, L.P. may be deemed to beneficially own the securities held by HighCape Partners, L.P. and HighCape Partners QP, L.P., and each of Mr. Rakin, Mr. Zuga and HighCape Capital, LLC may be deemed to beneficially own the securities held by HighCape Capital, L.P.

F3 · ownership.nature: In addition, Mr. Zuga is the managing member of each of HighCape Co-Investment Vehicle I, LLC and HighCape Co-Investment Vehicle II, LLC and may be deemed to beneficially own the securities held by such entities. Each of the reporting persons disclaims beneficial ownership of the securities held by the other reporting persons except to the extent of each reporting person's pecuniary interest therein, if any.

F4 · ownership.nature: HighCape Partners QP, L.P. is the record holder of these securities.

Read SEC document
October 13, 2020 Filed Oct 14, 2020 01:57 UTC ELUTIA INC. AZYO · Entity 7342 ConversionClass A Common Stock 4,062,451 $0.00 $0.00
Disclosure

SEC source: 0001104659-20-114637 · a4.xml · nonDerivative · entry 1

HighCape Capital, L.P. · CIK 0001826279 · 10% owner

HIGHCAPE PARTNERS, L.P. · CIK 0001598046 · 10% owner

HIGHCAPE PARTNERS QP, L.P. · CIK 0001598026 · 10% owner

HighCape Partners GP, LLC · CIK 0001819933 · 10% owner

HighCape Partners GP, L.P. · CIK 0001819932 · 10% owner

HighCape Co-Investment Vehicle I, LLC · CIK 0001819988 · 10% owner

HighCape Co-Investment Vehicle II, LLC · CIK 0001820044 · 10% owner

HighCape Capital, LLC · CIK 0001827500 · 10% owner

Zuga Matt · CIK 0001790214 · Director · 10% owner

RAKIN KEVIN · CIK 0001184421 · Director · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · Footnote

Disclosed balance after: 4,062,451

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · ownership.nature: Consists of (i) 43,255 shares of Class A common stock held by HighCape Partners, L.P.; (ii) 3,211,838 shares of Class A common stock held by HighCape Partners QP, L.P.; (iii) 499,145 shares of Class A common stock held by HighCape Co-Investment Vehicle I, LLC; (iv) 259,282 shares of Class A common stock held by HighCape Co-Investment Vehicle II, LLC and (v) 48,931 shares of Class A common stock held by HighCape Capital, L.P.

F2 · ownership.nature: Kevin Rakin and W. Matthew Zuga, members of Issuer's board of directors, are the managing members of HighCape Partners GP, LLC, which in turn is the general partner of HighCape Partners GP, L.P., which in turn is the general partner of each of HighCape Partners, L.P. and HighCape Partners QP, L.P. Mr. Rakin and Mr. Zuga are the managing members of HighCape Capital, LLC, which in turn is the general partner of HighCape Capital, L.P. Each of Mr. Rakin, Mr. Zuga, HighCape Partners GP, LLC and HighCape Partners GP, L.P. may be deemed to beneficially own the securities held by HighCape Partners, L.P. and HighCape Partners QP, L.P., and each of Mr. Rakin, Mr. Zuga and HighCape Capital, LLC may be deemed to beneficially own the securities held by HighCape Capital, L.P.

F3 · ownership.nature: In addition, Mr. Zuga is the managing member of each of HighCape Co-Investment Vehicle I, LLC and HighCape Co-Investment Vehicle II, LLC and may be deemed to beneficially own the securities held by such entities. Each of the reporting persons disclaims beneficial ownership of the securities held by the other reporting persons except to the extent of each reporting person's pecuniary interest therein, if any.

Read SEC document
January 08, 2020 Filed Jan 14, 2020 21:07 UTC ORAMED PHARMACEUTICALS INC. ORMP · Entity 6311 GrantStock Option (right to buy) · Derivative 20,000 $0.00 Strike: $4.80 $0.00
Disclosure

SEC source: 0001213900-20-000991 · ownership.xml · derivative · entry 1

RAKIN KEVIN · CIK 0001184421 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 20,000

Underlying: Common Stock · 20,000 shares

Expires 2030-01-08

F1 · derivative.exercise_date: The Stock Option will vest in 3 installments as follows: 6,666 shall vest on December 31, 2020, and 6,667 shall vest on each of December 31, 2021 and December 31, 2022.

Read SEC document
September 12, 2019 Filed Sep 16, 2019 22:08 UTC ORAMED PHARMACEUTICALS INC. ORMP · Entity 6311 GrantStock Option (right to buy) · Derivative 10,000 $0.00 Strike: $4.17 $0.00
Disclosure

SEC source: 0001213900-19-018200 · ownership.xml · derivative · entry 2

RAKIN KEVIN · CIK 0001184421 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 10,000

Underlying: Common Stock · 10,000 shares

Expires 2029-09-12

F1 · kind: The two reported transactions involved the cancellation of an outstanding option and the grant of a replacement option.

Read SEC document
April 10, 2019 Filed Apr 12, 2019 21:07 UTC ORAMED PHARMACEUTICALS INC. ORMP · Entity 6311 GrantStock Option (right to buy) · Derivative 10,000 $0.00 Strike: $4.17 $0.00
Disclosure

SEC source: 0001213900-19-006288 · ownership.xml · derivative · entry 1

RAKIN KEVIN · CIK 0001184421 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 10,000

Underlying: Common Stock · 10,000 shares

Expires 2029-04-10

Read SEC document
April 10, 2019 Filed Sep 16, 2019 22:08 UTC ORAMED PHARMACEUTICALS INC. ORMP · Entity 6311 Disposition to issuerStock Option (right to buy) · Derivative 10,000 $0.00 Strike: $4.17 $0.00
Disclosure

SEC source: 0001213900-19-018200 · ownership.xml · derivative · entry 1

RAKIN KEVIN · CIK 0001184421 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 10,000 shares

Expires 2029-04-10

F1 · kind: The two reported transactions involved the cancellation of an outstanding option and the grant of a replacement option.

Read SEC document
February 08, 2019 Filed Feb 11, 2019 21:26 UTC Ocugen, Inc. HSGX · Entity 5550 Exercise / conversionCommon Stock Warrant (Right to Buy) · Derivative 111,111 Not disclosed Strike: $0.01 Not disclosed
Disclosure

SEC source: 0000899243-19-003145 · doc4.xml · derivative · entry 8

RAKIN KEVIN · CIK 0001184421 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 0

Underlying: Common Stock · 111,111 shares

Expires 2021-11-22

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: The per share exercise price of each Common Stock Warrant was re-priced to $0.01 pursuant to a warrant exercise agreement entered into with the Issuer on February 8, 2019.

F4 · ownership.nature: The reportable securities are owned by the Kevin L Rakin Irrevocable Trust. The Reporting Person disclaims beneficial ownership of these shares and this report shall not be deemed an admission that he is the beneficial owner of such shares for purposes of Section 16 of the Exchange Act or for any other purpose, except to the extent of his pecuniary interest therein.

Read SEC document
February 08, 2019 Filed Feb 11, 2019 21:26 UTC Ocugen, Inc. HSGX · Entity 5550 Exercise / conversionCommon Stock Warrant (Right to Buy) · Derivative 33,333 Not disclosed Strike: $0.01 Not disclosed
Disclosure

SEC source: 0000899243-19-003145 · doc4.xml · derivative · entry 7

RAKIN KEVIN · CIK 0001184421 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 0

Underlying: Common Stock · 33,333 shares

Expires 2021-11-22

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: The per share exercise price of each Common Stock Warrant was re-priced to $0.01 pursuant to a warrant exercise agreement entered into with the Issuer on February 8, 2019.

F3 · ownership.nature: The reportable securities are owned by the Alison N Hoffman and Kevin L Rakin Irrevocable Trust For Julia Hoffman Rakin. The Reporting Person disclaims beneficial ownership of these shares and this report shall not be deemed an admission that he is the beneficial owner of such shares for purposes of Section 16 of the Exchange Act or for any other purpose, except to the extent of his pecuniary interest therein.

Read SEC document
February 08, 2019 Filed Feb 11, 2019 21:26 UTC Ocugen, Inc. HSGX · Entity 5550 Exercise / conversionCommon Stock Warrant (Right to Buy) · Derivative 33,333 Not disclosed Strike: $0.01 Not disclosed
Disclosure

SEC source: 0000899243-19-003145 · doc4.xml · derivative · entry 6

RAKIN KEVIN · CIK 0001184421 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 0

Underlying: Common Stock · 33,333 shares

Expires 2021-11-22

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: The per share exercise price of each Common Stock Warrant was re-priced to $0.01 pursuant to a warrant exercise agreement entered into with the Issuer on February 8, 2019.

F2 · ownership.nature: The reportable securities are owned by the Alison N Hoffman and Kevin L Rakin Irrevocable Trust For Sarah Hoffman Rakin. The Reporting Person disclaims beneficial ownership of these shares and this report shall not be deemed an admission that he is the beneficial owner of such shares for purposes of Section 16 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or for any other purpose, except to the extent of his pecuniary interest therein.

Read SEC document
February 08, 2019 Filed Feb 11, 2019 21:26 UTC Ocugen, Inc. HSGX · Entity 5550 Exercise / conversionCommon Stock Warrant (Right to Buy) · Derivative 173,076 Not disclosed Strike: $0.01 Not disclosed
Disclosure

SEC source: 0000899243-19-003145 · doc4.xml · derivative · entry 5

RAKIN KEVIN · CIK 0001184421 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 173,076 shares

Expires 2023-10-10

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: The per share exercise price of each Common Stock Warrant was re-priced to $0.01 pursuant to a warrant exercise agreement entered into with the Issuer on February 8, 2019.

Read SEC document
February 08, 2019 Filed Feb 11, 2019 21:26 UTC Ocugen, Inc. HSGX · Entity 5550 Exercise / conversionCommon Stock 111,111 Not disclosed Not disclosed
Disclosure

SEC source: 0000899243-19-003145 · doc4.xml · nonDerivative · entry 4

RAKIN KEVIN · CIK 0001184421 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 257,846

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: The per share exercise price of each Common Stock Warrant was re-priced to $0.01 pursuant to a warrant exercise agreement entered into with the Issuer on February 8, 2019.

F4 · ownership.nature: The reportable securities are owned by the Kevin L Rakin Irrevocable Trust. The Reporting Person disclaims beneficial ownership of these shares and this report shall not be deemed an admission that he is the beneficial owner of such shares for purposes of Section 16 of the Exchange Act or for any other purpose, except to the extent of his pecuniary interest therein.

Read SEC document
February 08, 2019 Filed Feb 11, 2019 21:26 UTC Ocugen, Inc. HSGX · Entity 5550 Exercise / conversionCommon Stock 33,333 Not disclosed Not disclosed
Disclosure

SEC source: 0000899243-19-003145 · doc4.xml · nonDerivative · entry 3

RAKIN KEVIN · CIK 0001184421 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 66,666

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: The per share exercise price of each Common Stock Warrant was re-priced to $0.01 pursuant to a warrant exercise agreement entered into with the Issuer on February 8, 2019.

F3 · ownership.nature: The reportable securities are owned by the Alison N Hoffman and Kevin L Rakin Irrevocable Trust For Julia Hoffman Rakin. The Reporting Person disclaims beneficial ownership of these shares and this report shall not be deemed an admission that he is the beneficial owner of such shares for purposes of Section 16 of the Exchange Act or for any other purpose, except to the extent of his pecuniary interest therein.

Read SEC document
February 08, 2019 Filed Feb 11, 2019 21:26 UTC Ocugen, Inc. HSGX · Entity 5550 Exercise / conversionCommon Stock 33,333 Not disclosed Not disclosed
Disclosure

SEC source: 0000899243-19-003145 · doc4.xml · nonDerivative · entry 2

RAKIN KEVIN · CIK 0001184421 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 66,666

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: The per share exercise price of each Common Stock Warrant was re-priced to $0.01 pursuant to a warrant exercise agreement entered into with the Issuer on February 8, 2019.

F2 · ownership.nature: The reportable securities are owned by the Alison N Hoffman and Kevin L Rakin Irrevocable Trust For Sarah Hoffman Rakin. The Reporting Person disclaims beneficial ownership of these shares and this report shall not be deemed an admission that he is the beneficial owner of such shares for purposes of Section 16 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or for any other purpose, except to the extent of his pecuniary interest therein.

Read SEC document
February 08, 2019 Filed Feb 11, 2019 21:26 UTC Ocugen, Inc. HSGX · Entity 5550 Exercise / conversionCommon Stock 173,076 Not disclosed Not disclosed
Disclosure

SEC source: 0000899243-19-003145 · doc4.xml · nonDerivative · entry 1

RAKIN KEVIN · CIK 0001184421 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 418,639

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: The per share exercise price of each Common Stock Warrant was re-priced to $0.01 pursuant to a warrant exercise agreement entered into with the Issuer on February 8, 2019.

Read SEC document
October 10, 2018 Filed Oct 11, 2018 20:30 UTC Ocugen, Inc. HSGX · Entity 5550 PurchaseCommon Stock Warrant (Right to Buy) · Derivative 173,076 Not disclosed Strike: $0.70 Not disclosed
Disclosure

SEC source: 0000899243-18-026561 · doc4.xml · derivative · entry 5

RAKIN KEVIN · CIK 0001184421 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 173,076

Underlying: Common Stock · 173,076 shares

Expires 2023-10-10

F1 · price: The Common Stock and Common Stock Warrants were issued and sold in a fixed combination at a purchase price of $0.65 per unit. Each share of Common Stock is accompanied by a Common Stock Warrant to purchase 0.75 shares of Common Stock, which are exercisable immediately for a period of 5 years from the date of issuance.

Read SEC document
October 10, 2018 Filed Oct 11, 2018 20:30 UTC Ocugen, Inc. HSGX · Entity 5550 PurchaseCommon Stock 230,768 Not disclosed Not disclosed
Disclosure

SEC source: 0000899243-18-026561 · doc4.xml · nonDerivative · entry 1

RAKIN KEVIN · CIK 0001184421 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 245,563

F1 · price: The Common Stock and Common Stock Warrants were issued and sold in a fixed combination at a purchase price of $0.65 per unit. Each share of Common Stock is accompanied by a Common Stock Warrant to purchase 0.75 shares of Common Stock, which are exercisable immediately for a period of 5 years from the date of issuance.

Read SEC document
June 15, 2018 Filed Jun 19, 2018 20:41 UTC Ocugen, Inc. HSGX · Entity 5550 GrantStock Option (Right to Buy) · Derivative 25,000 $0.00 Strike: $2.97 $0.00
Disclosure

SEC source: 0000899243-18-017189 · doc4.xml · derivative · entry 1

RAKIN KEVIN · CIK 0001184421 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 25,000

Underlying: Common Stock · 25,000 shares

Expires 2028-06-14

F1 · derivative.exercise_date: This option vests and becomes exercisable with respect to 8.33% of the option shares for each one-month period following June 15, 2018.

Read SEC document
June 30, 2017 Filed Jul 5, 2017 19:43 UTC ORAMED PHARMACEUTICALS INC. ORMP · Entity 6311 GrantStock Option (right to buy) · Derivative 56,773 $0.00 Strike: $7.77 $0.00
Disclosure

SEC source: 0001213900-17-007162 · f4063017rakin_oramed.xml · derivative · entry 1

RAKIN KEVIN · CIK 0001184421 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 56,773

Underlying: Common Stock · 56,773 shares

Expires 2027-06-30

F1 · derivative.exercise_date: The Stock Option will vest in 4 installments as follows: 15,591 on each of December 31, 2017, December 31, 2018 and December 31, 2019, and 10,000 on December 31, 2020.

Read SEC document
June 13, 2017 Filed Jun 14, 2017 21:02 UTC Ocugen, Inc. HSGX · Entity 5550 GrantStock Option (Right to Buy) · Derivative 25,000 $0.00 Strike: $1.70 $0.00
Disclosure

SEC source: 0000899243-17-016395 · doc4.xml · derivative · entry 1

RAKIN KEVIN · CIK 0001184421 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 25,000

Underlying: Common Stock · 25,000 shares

Expires 2027-06-12

F1 · derivative.exercise_date: This option vests and becomes exercisable with respect to 8.33% of the option shares for each one-month period following June 13, 2017.

Read SEC document
February 09, 2017 Filed Feb 16, 2017 20:45 UTC ORAMED PHARMACEUTICALS INC. ORMP · Entity 6311 GrantStock Option (right to buy) · Derivative 5,697 $0.00 Strike: $6.23 $0.00
Disclosure

SEC source: 0001213900-17-001490 · f4020917rakin_oramed.xml · derivative · entry 1

RAKIN KEVIN · CIK 0001184421 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,697

Underlying: Common Stock · 5,697 shares

Expires 2027-02-09

F1 · derivative.exercise_date: The Stock Option will vest immediately.

Read SEC document
December 16, 2016 Filed Dec 19, 2016 22:00 UTC Ocugen, Inc. HSGX · Entity 5550 GrantStock Option (Right to Buy) · Derivative 10,000 $0.00 Strike: $1.58 $0.00
Disclosure

SEC source: 0000899243-16-035942 · doc4.xml · derivative · entry 1

RAKIN KEVIN · CIK 0001184421 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 10,000

Underlying: Common Stock · 10,000 shares

Expires 2026-12-16

F1 · derivative.exercise_date: This option vests and becomes exercisable with respect to 8.33% of the option shares for each one-month period following June 22, 2016.

Read SEC document
December 06, 2016 Filed Dec 7, 2016 16:11 UTC ORAMED PHARMACEUTICALS INC. ORMP · Entity 6311 GrantCommon Stock 3,300 $6.59 $21,762.84
Disclosure

SEC source: 0001213900-16-019206 · f4120516rakin_oramedpharma.xml · nonDerivative · entry 2

RAKIN KEVIN · CIK 0001184421 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 15,061

F2 · price: This transaction was executed in multiple trades at prices ranging from $6.40 to $6.65. The price reported above in Column 4 of Table I reflects the weighted average purchase price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer complete information regarding the number of shares and prices at which each of the individual transactions was effected.

Read SEC document
December 05, 2016 Filed Dec 7, 2016 16:11 UTC ORAMED PHARMACEUTICALS INC. ORMP · Entity 6311 GrantCommon Stock 2,300 $6.38 $14,665.03
Disclosure

SEC source: 0001213900-16-019206 · f4120516rakin_oramedpharma.xml · nonDerivative · entry 1

RAKIN KEVIN · CIK 0001184421 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 11,761

F1 · price: This transaction was executed in multiple trades at prices ranging from $6.36 to $6.39. The price reported above in Column 4 of Table I reflects the weighted average purchase price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer complete information regarding the number of shares and prices at which each of the individual transactions was effected.

Read SEC document
December 02, 2016 Filed Dec 5, 2016 19:24 UTC ORAMED PHARMACEUTICALS INC. ORMP · Entity 6311 GrantCommon Stock 7,261 $6.21 $45,057.41
Disclosure

SEC source: 0001213900-16-019147 · f4120116rakin_oramed.xml · nonDerivative · entry 2

RAKIN KEVIN · CIK 0001184421 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 9,461

F2 · price: This transaction was executed in multiple trades at prices ranging from $6.07 to $6.30. The price reported above in Column 4 of Table I reflects the weighted average purchase price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer complete information regarding the number of shares and prices at which each of the individual transactions was effected.

Read SEC document
December 01, 2016 Filed Dec 5, 2016 19:24 UTC ORAMED PHARMACEUTICALS INC. ORMP · Entity 6311 GrantCommon Stock 2,200 $6.08 $13,370.94
Disclosure

SEC source: 0001213900-16-019147 · f4120116rakin_oramed.xml · nonDerivative · entry 1

RAKIN KEVIN · CIK 0001184421 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,200

F1 · price: This transaction was executed in multiple trades at prices ranging from $6.00 to $6.15. The price reported above in Column 4 of Table I reflects the weighted average purchase price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer complete information regarding the number of shares and prices at which each of the individual transactions was effected.

Read SEC document
November 30, 2016 Filed Dec 2, 2016 22:00 UTC Ocugen, Inc. HSGX · Entity 5550 ConversionSeries A Convertible Preferred Stock · Derivative 200.2455 $0.00 $0.00
Disclosure

SEC source: 0000899243-16-034850 · doc4.xml · derivative · entry 6

RAKIN KEVIN · CIK 0001184421 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 0

Underlying: Common Stock · 88,998 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: All outstanding shares of the Issuer's Series A Convertible Preferred Stock converted on a 1:444.444444 basis into shares of the Issuer's Common Stock. These shares have no expiration date.

F1 · shares: All outstanding shares of the Issuer's Series A Convertible Preferred Stock converted on a 1:444.444444 basis into shares of the Issuer's Common Stock. These shares have no expiration date.

F1 · derivative.exercise_date: All outstanding shares of the Issuer's Series A Convertible Preferred Stock converted on a 1:444.444444 basis into shares of the Issuer's Common Stock. These shares have no expiration date.

F1 · derivative.expiration_date: All outstanding shares of the Issuer's Series A Convertible Preferred Stock converted on a 1:444.444444 basis into shares of the Issuer's Common Stock. These shares have no expiration date.

F1 · derivative.underlying_shares: All outstanding shares of the Issuer's Series A Convertible Preferred Stock converted on a 1:444.444444 basis into shares of the Issuer's Common Stock. These shares have no expiration date.

F4 · ownership.nature: The reportable securities are owned by the Kevin L Rakin Irrevocable Trust. The Reporting Person disclaims beneficial ownership of these shares and this report shall not be deemed an admission that he is the beneficial owner of such shares for purposes of Section 16 of the Exchange Act or for any other purpose, except to the extent of his pecuniary interest therein.

Read SEC document
November 30, 2016 Filed Dec 2, 2016 22:00 UTC Ocugen, Inc. HSGX · Entity 5550 ConversionSeries A Convertible Preferred Stock · Derivative 60.0728 $0.00 $0.00
Disclosure

SEC source: 0000899243-16-034850 · doc4.xml · derivative · entry 5

RAKIN KEVIN · CIK 0001184421 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 0

Underlying: Common Stock · 26,699 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: All outstanding shares of the Issuer's Series A Convertible Preferred Stock converted on a 1:444.444444 basis into shares of the Issuer's Common Stock. These shares have no expiration date.

F1 · shares: All outstanding shares of the Issuer's Series A Convertible Preferred Stock converted on a 1:444.444444 basis into shares of the Issuer's Common Stock. These shares have no expiration date.

F1 · derivative.exercise_date: All outstanding shares of the Issuer's Series A Convertible Preferred Stock converted on a 1:444.444444 basis into shares of the Issuer's Common Stock. These shares have no expiration date.

F1 · derivative.expiration_date: All outstanding shares of the Issuer's Series A Convertible Preferred Stock converted on a 1:444.444444 basis into shares of the Issuer's Common Stock. These shares have no expiration date.

F1 · derivative.underlying_shares: All outstanding shares of the Issuer's Series A Convertible Preferred Stock converted on a 1:444.444444 basis into shares of the Issuer's Common Stock. These shares have no expiration date.

F3 · ownership.nature: The reportable securities are owned by the Alison N Hoffman and Kevin L Rakin Irrevocable Trust For Julia Hoffman Rakin. The Reporting Person disclaims beneficial ownership of these shares and this report shall not be deemed an admission that he is the beneficial owner of such shares for purposes of Section 16 of the Exchange Act or for any other purpose, except to the extent of his pecuniary interest therein.

Read SEC document
November 30, 2016 Filed Dec 2, 2016 22:00 UTC Ocugen, Inc. HSGX · Entity 5550 ConversionSeries A Convertible Preferred Stock · Derivative 60.0728 $0.00 $0.00
Disclosure

SEC source: 0000899243-16-034850 · doc4.xml · derivative · entry 4

RAKIN KEVIN · CIK 0001184421 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 0

Underlying: Common Stock · 26,699 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: All outstanding shares of the Issuer's Series A Convertible Preferred Stock converted on a 1:444.444444 basis into shares of the Issuer's Common Stock. These shares have no expiration date.

F1 · shares: All outstanding shares of the Issuer's Series A Convertible Preferred Stock converted on a 1:444.444444 basis into shares of the Issuer's Common Stock. These shares have no expiration date.

F1 · derivative.exercise_date: All outstanding shares of the Issuer's Series A Convertible Preferred Stock converted on a 1:444.444444 basis into shares of the Issuer's Common Stock. These shares have no expiration date.

F1 · derivative.expiration_date: All outstanding shares of the Issuer's Series A Convertible Preferred Stock converted on a 1:444.444444 basis into shares of the Issuer's Common Stock. These shares have no expiration date.

F1 · derivative.underlying_shares: All outstanding shares of the Issuer's Series A Convertible Preferred Stock converted on a 1:444.444444 basis into shares of the Issuer's Common Stock. These shares have no expiration date.

F2 · ownership.nature: The reportable securities are owned by the Alison N Hoffman and Kevin L Rakin Irrevocable Trust For Sarah Hoffman Rakin. The Reporting Person disclaims beneficial ownership of these shares and this report shall not be deemed an admission that he is the beneficial owner of such shares for purposes of Section 16 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or for any other purpose, except to the extent of his pecuniary interest therein.

Read SEC document
November 30, 2016 Filed Dec 2, 2016 22:00 UTC Ocugen, Inc. HSGX · Entity 5550 ConversionCommon Stock 88,998 Not disclosed Not disclosed
Disclosure

SEC source: 0000899243-16-034850 · doc4.xml · nonDerivative · entry 3

RAKIN KEVIN · CIK 0001184421 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 228,196

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · shares: All outstanding shares of the Issuer's Series A Convertible Preferred Stock converted on a 1:444.444444 basis into shares of the Issuer's Common Stock. These shares have no expiration date.

F1 · price: All outstanding shares of the Issuer's Series A Convertible Preferred Stock converted on a 1:444.444444 basis into shares of the Issuer's Common Stock. These shares have no expiration date.

F4 · ownership.nature: The reportable securities are owned by the Kevin L Rakin Irrevocable Trust. The Reporting Person disclaims beneficial ownership of these shares and this report shall not be deemed an admission that he is the beneficial owner of such shares for purposes of Section 16 of the Exchange Act or for any other purpose, except to the extent of his pecuniary interest therein.

Read SEC document
November 30, 2016 Filed Dec 2, 2016 22:00 UTC Ocugen, Inc. HSGX · Entity 5550 ConversionCommon Stock 26,699 Not disclosed Not disclosed
Disclosure

SEC source: 0000899243-16-034850 · doc4.xml · nonDerivative · entry 2

RAKIN KEVIN · CIK 0001184421 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 139,198

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · shares: All outstanding shares of the Issuer's Series A Convertible Preferred Stock converted on a 1:444.444444 basis into shares of the Issuer's Common Stock. These shares have no expiration date.

F1 · price: All outstanding shares of the Issuer's Series A Convertible Preferred Stock converted on a 1:444.444444 basis into shares of the Issuer's Common Stock. These shares have no expiration date.

F3 · ownership.nature: The reportable securities are owned by the Alison N Hoffman and Kevin L Rakin Irrevocable Trust For Julia Hoffman Rakin. The Reporting Person disclaims beneficial ownership of these shares and this report shall not be deemed an admission that he is the beneficial owner of such shares for purposes of Section 16 of the Exchange Act or for any other purpose, except to the extent of his pecuniary interest therein.

Read SEC document
November 30, 2016 Filed Dec 2, 2016 22:00 UTC Ocugen, Inc. HSGX · Entity 5550 ConversionCommon Stock 26,699 Not disclosed Not disclosed
Disclosure

SEC source: 0000899243-16-034850 · doc4.xml · nonDerivative · entry 1

RAKIN KEVIN · CIK 0001184421 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 112,499

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · shares: All outstanding shares of the Issuer's Series A Convertible Preferred Stock converted on a 1:444.444444 basis into shares of the Issuer's Common Stock. These shares have no expiration date.

F1 · price: All outstanding shares of the Issuer's Series A Convertible Preferred Stock converted on a 1:444.444444 basis into shares of the Issuer's Common Stock. These shares have no expiration date.

F2 · ownership.nature: The reportable securities are owned by the Alison N Hoffman and Kevin L Rakin Irrevocable Trust For Sarah Hoffman Rakin. The Reporting Person disclaims beneficial ownership of these shares and this report shall not be deemed an admission that he is the beneficial owner of such shares for purposes of Section 16 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or for any other purpose, except to the extent of his pecuniary interest therein.

Read SEC document
September 29, 2016 Filed Oct 3, 2016 21:15 UTC Ocugen, Inc. HSGX · Entity 5550 GrantCommon Stock Warrant (Right to Buy) · Derivative 111,111 $0.00 Strike: $2.25 $0.00
Disclosure

SEC source: 0000899243-16-030577 · doc4.xml · derivative · entry 9

RAKIN KEVIN · CIK 0001184421 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 177,777

Underlying: Common Stock · 111,111 shares

Expires not disclosed

F5 · derivative.exercise_date: The Common Stock Warrants are exercisable at any time on or after the date (the "Initial Exercise Date") that the Company's stockholders approve the transactions contemplated by that certain securities purchase agreement dated September 15, 2016 pursuant to which the warrants were issued through the close of business on the five year anniversary of the Initial Exercise Date.

F5 · derivative.expiration_date: The Common Stock Warrants are exercisable at any time on or after the date (the "Initial Exercise Date") that the Company's stockholders approve the transactions contemplated by that certain securities purchase agreement dated September 15, 2016 pursuant to which the warrants were issued through the close of business on the five year anniversary of the Initial Exercise Date.

F3 · ownership.nature: The reportable securities are owned by the Kevin L Rakin Irrevocable Trust. The Reporting Person disclaims beneficial ownership of these shares and this report shall not be deemed an admission that he is the beneficial owner of such shares for purposes of Section 16 of the Exchange Act or for any other purpose, except to the extent of his pecuniary interest therein.

Read SEC document
September 29, 2016 Filed Oct 3, 2016 21:15 UTC Ocugen, Inc. HSGX · Entity 5550 GrantCommon Stock Warrant (Right to Buy) · Derivative 33,333 $0.00 Strike: $2.25 $0.00
Disclosure

SEC source: 0000899243-16-030577 · doc4.xml · derivative · entry 8

RAKIN KEVIN · CIK 0001184421 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 66,666

Underlying: Common Stock · 33,333 shares

Expires not disclosed

F5 · derivative.exercise_date: The Common Stock Warrants are exercisable at any time on or after the date (the "Initial Exercise Date") that the Company's stockholders approve the transactions contemplated by that certain securities purchase agreement dated September 15, 2016 pursuant to which the warrants were issued through the close of business on the five year anniversary of the Initial Exercise Date.

F5 · derivative.expiration_date: The Common Stock Warrants are exercisable at any time on or after the date (the "Initial Exercise Date") that the Company's stockholders approve the transactions contemplated by that certain securities purchase agreement dated September 15, 2016 pursuant to which the warrants were issued through the close of business on the five year anniversary of the Initial Exercise Date.

F2 · ownership.nature: The reportable securities are owned by the Alison N Hoffman and Kevin L Rakin Irrevocable Trust For Julia Hoffman Rakin. The Reporting Person disclaims beneficial ownership of these shares and this report shall not be deemed an admission that he is the beneficial owner of such shares for purposes of Section 16 of the Exchange Act or for any other purpose, except to the extent of his pecuniary interest therein.

Read SEC document
September 29, 2016 Filed Oct 3, 2016 21:15 UTC Ocugen, Inc. HSGX · Entity 5550 GrantCommon Stock Warrant (Right to Buy) · Derivative 33,333 $0.00 Strike: $2.25 $0.00
Disclosure

SEC source: 0000899243-16-030577 · doc4.xml · derivative · entry 7

RAKIN KEVIN · CIK 0001184421 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 33,333

Underlying: Common Stock · 33,333 shares

Expires not disclosed

F5 · derivative.exercise_date: The Common Stock Warrants are exercisable at any time on or after the date (the "Initial Exercise Date") that the Company's stockholders approve the transactions contemplated by that certain securities purchase agreement dated September 15, 2016 pursuant to which the warrants were issued through the close of business on the five year anniversary of the Initial Exercise Date.

F5 · derivative.expiration_date: The Common Stock Warrants are exercisable at any time on or after the date (the "Initial Exercise Date") that the Company's stockholders approve the transactions contemplated by that certain securities purchase agreement dated September 15, 2016 pursuant to which the warrants were issued through the close of business on the five year anniversary of the Initial Exercise Date.

F1 · ownership.nature: The reportable securities are owned by the Alison N Hoffman and Kevin L Rakin Irrevocable Trust For Sarah Hoffman Rakin. The Reporting Person disclaims beneficial ownership of these shares and this report shall not be deemed an admission that he is the beneficial owner of such shares for purposes of Section 16 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or for any other purpose, except to the extent of his pecuniary interest therein.

Read SEC document
September 29, 2016 Filed Oct 3, 2016 21:15 UTC Ocugen, Inc. HSGX · Entity 5550 GrantSeries A Convertible Preferred Stock · Derivative 200.2455 $1,000.00 $200,245.50
Disclosure

SEC source: 0000899243-16-030577 · doc4.xml · derivative · entry 6

RAKIN KEVIN · CIK 0001184421 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 320.3911

Underlying: Common Stock · 88,998 shares

Expires not disclosed

F4 · derivative.exercise_price: The shares of Series A Convertible Preferred Stock have a stated value of $1,000 per share and will be convertible into shares of the Issuer's Common Stock, subject to certain conditions including the receipt of requisite stockholder approval pursuant to the Certificate of Designation governing the rights, preferences and privileges of the Series A Convertible Preferred Stock. The initial conversion price of $2.25 is subject to appropriate adjustment in the event of a stock split, stock dividend, combination, reclassification or other recapitalization affecting the Issuer's Common Stock

F4 · shares: The shares of Series A Convertible Preferred Stock have a stated value of $1,000 per share and will be convertible into shares of the Issuer's Common Stock, subject to certain conditions including the receipt of requisite stockholder approval pursuant to the Certificate of Designation governing the rights, preferences and privileges of the Series A Convertible Preferred Stock. The initial conversion price of $2.25 is subject to appropriate adjustment in the event of a stock split, stock dividend, combination, reclassification or other recapitalization affecting the Issuer's Common Stock

F4 · derivative.exercise_date: The shares of Series A Convertible Preferred Stock have a stated value of $1,000 per share and will be convertible into shares of the Issuer's Common Stock, subject to certain conditions including the receipt of requisite stockholder approval pursuant to the Certificate of Designation governing the rights, preferences and privileges of the Series A Convertible Preferred Stock. The initial conversion price of $2.25 is subject to appropriate adjustment in the event of a stock split, stock dividend, combination, reclassification or other recapitalization affecting the Issuer's Common Stock

F4 · derivative.expiration_date: The shares of Series A Convertible Preferred Stock have a stated value of $1,000 per share and will be convertible into shares of the Issuer's Common Stock, subject to certain conditions including the receipt of requisite stockholder approval pursuant to the Certificate of Designation governing the rights, preferences and privileges of the Series A Convertible Preferred Stock. The initial conversion price of $2.25 is subject to appropriate adjustment in the event of a stock split, stock dividend, combination, reclassification or other recapitalization affecting the Issuer's Common Stock

F4 · derivative.underlying_shares: The shares of Series A Convertible Preferred Stock have a stated value of $1,000 per share and will be convertible into shares of the Issuer's Common Stock, subject to certain conditions including the receipt of requisite stockholder approval pursuant to the Certificate of Designation governing the rights, preferences and privileges of the Series A Convertible Preferred Stock. The initial conversion price of $2.25 is subject to appropriate adjustment in the event of a stock split, stock dividend, combination, reclassification or other recapitalization affecting the Issuer's Common Stock

F3 · ownership.nature: The reportable securities are owned by the Kevin L Rakin Irrevocable Trust. The Reporting Person disclaims beneficial ownership of these shares and this report shall not be deemed an admission that he is the beneficial owner of such shares for purposes of Section 16 of the Exchange Act or for any other purpose, except to the extent of his pecuniary interest therein.

Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.